Summary
The in vivo effects of the oxazaphosphorine compound ifosfamide (IFO) on human tumour xenografts were assessed in thymus aplastic nude mice. The human origin of the tumours was confirmed by isoenzymatic and immunohistochemical methods. Tumour models were selected from a panel of 180 regularly growing, well-characterized xenografts. The maximum tolerated dose in tumour-bearing nude mice was determined to be 130 mg/kg per day given on days 1–3 and 15–17. After 21 days, lethality was 14% after i.p. and 6% after s.c. administration. A total of 43 human tumours were tested for antineoplastic activity, 15 of which (36%) showed regression: 4/5 breast cancer xenografts, 1/3 colon, 1/1 gastric, 2/7 non-small-cell lung cancers (NSCLC), 3/4 small-cell lung cancers (SCLC), 1/2 sarcomas and 3/3 testicular cancers. Two ovarian, two uterine and six renal cancer xenografts as well as three melanomas and five tumours of various histologies were resistant. In 30 human tumour xenografts, the antineoplastic efficacy of the two oxazaphosphorine derivatives cyclophosphamide and IFO was compared. The maximum tolerated dose of cyclophosphamide was 200 mg/kg per day given i.p. on days 1 and 15; it led to 17% lethality after 21 days. Cyclophosphamide induced tumour regression or remission in 10/30 xenografts (33%) and IFO in 13/30 (43%). In conclusion, the observed efficacy of IFO parallels the clinical situation. Breast, lung and testicular cancer and sarcomas proved to be responsive. The antitumoural activity of IFO shows similarities to that of cyclophosphamide; however, a higher response rate and lower toxicity were noted for the former. Preclinical phase II studies in nude mice seem to offer an effective way of identifying active drugs as well as sensitive tumour types for further clinical development.
Similar content being viewed by others
References
Antman KH, Montella D, Rosenbaum C, Schwen M (1985) Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma. Cancer Treat Rep 69: 499–504
Brock N, Pohl J (1987) The basis of modern ifosfamide therapy. In: Contributions to Oncology, vol 26, Karger, Basel, pp 1–11
Cabanillas F (1987) Ifosfamide combinations in the management of lymphomas. In: Contributions to Oncology, vol 26. Karger, Basel, pp 394–399
Coleman RE, Harper PG, Rankin E, Wiltshaw E, Calvert H, Osborne R, Slevin ML, Souhami R, Silverstone AC, Trask CW (1985) A phase II study of ifosfamide in advanced relapsed carcinoma of the cervix [Abstr 460]. 3rd European Conference on Clinical Oncology and Cancer Nursing, Stockholm, June 16–20, p 1095
Dietel M, Arps H, Niendorf A, Hölzel F (1987) Effectiveness of ifosfamide on human tumor cells in culture using a monolayer proliferation assay. In: Contributions to Oncology, vol 26. Karger, Basel, pp 60–68
Drings P (1987) Ifosfamide in the treatment of bronchial carcinoma. In: Contributions to Oncology, vol 26. Karger, Basel, pp 294–318
Drings P, Manke HG (1985) Die Behandlung des nichtkleinzelligen Bronchialkarzinoms mit Cisplatin, Ifosfamid, Vindesin und VP16. Strahlentherapie 161: 131–133
Druckrey H (1973) Krebs—experimentelle Ursachenforschung und Chemotherapie. Z Krebsgeschehen 7: 73
Fiebig HH (1988) Comparison of tumor response in nude mice and in patients. In: Winograd B, Peckham MJ, Pinedo HM (eds) Human tumour xenografts in anticancer drug development. Springer, Berlin Heidelberg New York London Paris Tokyo, pp 25–30
Fiebig HH, Löhr GW (1984) Wachstum menschlicher Malignome in der thymusaplastischen Nacktmaus. Med Welt 35: 52–58, 81–86
Fortmeyer HP, Bastert G (1981) Breeding and maintenance of nu/nu mice and rnu/rnu rats. In: Bastert G, Fortmeyer HP, Schmidt-Mathiesen H (eds) Thymus aplastic nude mice and rats in clinical oncology. G. Fischer, Stuttgart New York, pp 25–38
Goldin A, Venditti JM, Kline I (1977) Preclinical investigations with ifosfamide in relation to cyclophosphamide. Proceedings, International Holoxan Symposium, Düsseldorf. Asta-Werke, Bielefeld, pp 19–28
Hartlapp JH, Weißbach L, Horstmann Dubral B (1987) Ifosfamide monotherapy in testicular cancer. In: Contributions to Oncology, vol 26. Karger, Basel, pp 256–261
Hartlapp JH, Illiger HJ, Wolter H (1987) Alternatives to CYVADIC combination therapy of soft tissue sarcomas. In: Contributions to Oncology, vol 26. Karger, Basel, pp 145–152
Klein HO, Wickramanayake PD, Coerper C, Christian E, Pohe J, Brock N (1983) High-dose ifosfamide and mesna as continuous infusion over five days — a phase I/II trial. Cancer Treat Rev 10 (Suppl. A) 167–173
Lange O (1987) Behandlung des fortgeschrittenen metastasierten Mammakarzinoms. Münch Med Wochenschr 129: 361–363
Schmoll HJ (1987) The role of ifosfamide in testicular cancer. In: Contributions to Oncology, vol 26. Karger, Basel, pp 234–255
Steel GG, Courtenay VD, Peckham MJ (1982) The immunesuppressed mouse as an alternative host for heterotransplantation. In: Fogh J (ed) The nude mouse in experimental and clinical research, vol 2. Academic Press, New York, pp 207–227
Varini M (1987) Ifosfamide in tumor therapy — an overview. In: Contributions to Oncology, vol 26. Karger, Basel, pp 12–21
Yakushiji M, Tsunawaki A, Nishida T, Nishimura H, Natsuaki Y, Inoue T, Kato T (1981) Chemotherapy of malignant ovarian tumors; therapeutic results of ifosfamide. Acta Obstet Gynaecol Jpn Engl Ed 55: 1071–1076
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Berger, D.P., Fiebig, H.H., Winterhalter, B.R. et al. Preclinical phase II study of ifosfamide in human tumour xenografts in vivo. Cancer Chemother. Pharmacol. 26 (Suppl 1), S7–S11 (1990). https://doi.org/10.1007/BF00685408
Issue Date:
DOI: https://doi.org/10.1007/BF00685408